Novartis and Versant to form biotech venture Borealis Biosciences
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
The emergence of new infections in India is a growing concern
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated